pharma · Alzheimer Disease · Amyotrophic Lateral Sclerosis · AMLX
Amylyx Pharmaceuticals EMEA
Amylyx Pharmaceuticals EMEA B.V.
Amylyx Pharmaceuticals EMEA is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker AMLX. Primary therapeutic focus areas include Alzheimer Disease, Amyotrophic Lateral Sclerosis, Progres
Cambridge, USA HQ
167 Employees
Public company Type
AMLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 167
- Programs
- 7
- Drugs
- 2
- Patents
- 9
AMX0035
Phase 2 · small molecule · Wolfram Syndrome
AMX0035 for Wolfram Syndrome is a Phase 2 program (small_molecule) at Amylyx Pharmaceuticals EMEA B.V. with 1 ClinicalTrials.gov record(s).
Internal code A35-008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Amylyx Pharmaceuticals EMEA B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Wolfram Syndrome
- Status
- active
- Trials
- 1